HC Wainwright Lowers Jasper Therapeutics (NASDAQ:JSPR) Price Target to $40.00

Jasper Therapeutics (NASDAQ:JSPR) had its price target decreased by HC Wainwright from $60.00 to $40.00 in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Jasper Therapeutics’ FY2029 earnings at ($10.81) EPS.

Other analysts have also recently issued research reports about the stock. BMO Capital Markets started coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, Royal Bank of Canada decreased their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $67.75.

Jasper Therapeutics Stock Performance

NASDAQ JSPR opened at $7.05 on Friday. The stock has a market cap of $105.76 million, a P/E ratio of -1.49 and a beta of 2.18. Jasper Therapeutics has a fifty-two week low of $6.57 and a fifty-two week high of $31.01. The stock has a 50 day simple moving average of $21.37 and a two-hundred day simple moving average of $20.27.

Institutional Trading of Jasper Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its holdings in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after acquiring an additional 1,698 shares in the last quarter. American Century Companies Inc. boosted its stake in Jasper Therapeutics by 27.1% in the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after purchasing an additional 3,032 shares in the last quarter. Wolff Wiese Magana LLC purchased a new stake in Jasper Therapeutics during the 3rd quarter valued at about $59,000. Fernwood Investment Management LLC increased its stake in Jasper Therapeutics by 6.9% during the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock valued at $995,000 after purchasing an additional 3,427 shares in the last quarter. Finally, MetLife Investment Management LLC raised its holdings in Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after buying an additional 3,873 shares during the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.